Docetaxel chemotherapy of Korean patients with hormone-refractory prostate cancer: Comparative analysis between 1st-line and 2nd-line docetaxel

Yonsei Medical Journal

Volumn 49, Issue 5, 2008, Pages 775-782

  Joung, Jae Young ^a   Jeong, In Gab ^a   Han, Kyung Seok ^a   Kim, Taek Sang ^a   Yang, Seung Ok ^a   Seo, Ho Kyung ^a   Chung, Jinsoo ^a   Cho, Kang Su ^a   Lee, Kang Hyun ^a  

^a National Cancer Center   (South Korea)

Author keywords

Chemotherapy; Docetaxel; Prostate neoplasm

Indexed keywords

ANTIANDROGEN; ANTIBIOTIC AGENT; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; GONADORELIN DERIVATIVE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FEBRILE NEUTROPENIA; FLUID THERAPY; HUMAN; KOREA; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 58149462252     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2008.49.5.775     Document Type: Article

References (21)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E, Shin HR, et al. Rising prostate cancer rates in South Korea. Prostate 2006;66:1285-91.
3. McLeod DC. Hormonal therapy in the treatment of carcinoma of the prostate. Cancer 1995;75 Suppl 7:1914-9.
4. Huggins C, Hodges CV. Studies on prostatic cancer: I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 1972;22:232-40.
5. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-24.
6. Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339:1036-42.
7. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al; TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cacner. N Engl J Med 2004;351:1502-12.
8. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
9. Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 2004;22:537-56.
10. Therasse P Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 2000;92:205-16.
11. Kreis W, Budman DR, Calabro A. Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Urol 1997;79:196-202.
12. Díaz JF, Andreu JM. Assembly of purified GDP-tubutin into microtubules induced by taxol and taxotere: reversibility, ligand stoichiometry, and competition. Biochemistry 1993;32:2747-55.
13. Haldar S, Basu A, Croce CM. Bc12 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
14. Miyoshi Y, Uemura H, Nakamura M, Hasumi H, Sugiura S, Makiyama K, et al. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients. Int J Clin Oncol 2005;10: 182-6.
15. Akaza H, Moore MA, Chang SJ, Cheng C, Choi HY, Esuvaranathaw K, et al. The 5th conference on Asian Trends in prostate cancer hormone therapy. Asian Pac J Cancer Prev 2007;8:3-12.
16. Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Intern Med J 2005;35:468-72.
17. Michels J, Montermurro T, Murray N, Kollmannsberger C, Nguyen Chi K. First- and second line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006;106:1041-6.
18. Berthold DR, Sternberg CN, Tannock IF. Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 2005;23:8247-52.
19. Calabrò F, Sternberg CN. Current indications for chemotherapy in prostate cancer patients. Fur Urol 2007;51:17-26.
20. Pienta KJ, Smith DC. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 2005;55:300-18; quiz 323-5.
21. Mendiratta P, Armstrong AJ, George DJ. Current standard and investigational approaches to the management of hormone-refractory prostate cancer. Rev Urol 2007;9 Suppl 1:S9-S19.